At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.

HRP-Protector is a long-term stabilizer for horseradish peroxidase (HRP) coupled to antibodies or Neutravidin/Streptavidin.

The Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis.

The cells’ surrounding structures play an important role as cues from the immune system in guiding their motility and behaviour, researchers from the UK and the US report.

The recently released IACG report testifies that the antimicrobial resistance (AMR) problem is now receiving some echo at the political level. Literature exploring ways to fix the acknowledged market failure is growing. Stakeholder meetings deciphering the impact of the proposed models are being organised all over the world. Still, time is against us.

An enzyme that clears out alpha-synuclein from neurons may counteract Parkinson’s Disease, report researchers from ETH Zürich and Novartis.

Under a partnering ageement with CEPI, Themis Bioscience will receive $21m to push pivotal testing of MV-CHIK, its Chikungunya vaccine candidate.

A fungus that produces an insecticide can stop the spread of Anopheles mosquito, which causes malaria.

European pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment". 

Sanofi has a new head of development, which the company confirmed on Wednesday with a short tweet: "Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients."